Yazılar

Microsoft Targets $50B AI Investment in Global South

/in /tarafından

Microsoft announced plans to invest up to $50 billion by the end of the decade to expand artificial intelligence infrastructure across developing and emerging economies, commonly referred to as the Global South.

The commitment was revealed during the AI summit held in New Delhi, where technology leaders and policymakers gathered to discuss the future of digital transformation in lower-income regions.

The Global South includes nations primarily located in the southern hemisphere that are still building their technological and economic capacity. Microsoft’s initiative aims to accelerate AI adoption in these regions by improving infrastructure and access to advanced digital tools.

India remains a central focus of this strategy. Last year, Microsoft unveiled $17.5 billion in AI-related investments in the country, reinforcing its position as a key growth market with rapidly expanding digital demand.

The broader initiative reflects increasing efforts by major technology companies to extend AI capabilities beyond traditional technology hubs, enabling wider participation in the global digital economy.

Microsoft rolls out next generation of its AI chips, takes aim at Nvidia’s software

/in /tarafından

Microsoft has unveiled the second generation of its in-house artificial intelligence chip, Maia 200, alongside new software tools designed to challenge Nvidia’s dominance among AI developers. The chip is going live this week at a Microsoft data center in Iowa, with a second deployment planned in Arizona, marking a key step in the company’s effort to reduce reliance on external chip suppliers.

The Maia 200 follows Microsoft’s first Maia chip introduced in 2023 and arrives as major cloud providers increasingly develop their own AI hardware. Companies such as Google and Amazon Web Services, traditionally large Nvidia customers, are now rolling out custom chips that compete directly with Nvidia’s offerings. The shift reflects growing demand for tailored AI infrastructure optimized for large-scale cloud workloads.

Alongside the new chip, Microsoft announced a suite of software tools to support developers, including Triton, an open-source programming framework that performs similar functions to Nvidia’s widely used Cuda software. By strengthening its software ecosystem, Microsoft is targeting what many analysts view as Nvidia’s most significant competitive advantage.

The Maia 200 is manufactured by Taiwan Semiconductor Manufacturing Company using advanced 3-nanometer technology and incorporates high-bandwidth memory. Microsoft has also emphasized the use of SRAM, a fast memory type that can improve performance for AI systems handling large volumes of user requests, a design choice increasingly favored by Nvidia’s emerging competitors.

Bristol Myers Partners With Microsoft for AI-Driven Lung Cancer Detection

/in /tarafından

Bristol Myers Squibb has signed a partnership with Microsoft to use artificial intelligence-powered radiology tools to speed up the early detection of lung cancer, the companies said on Tuesday.

Under the agreement, Bristol Myers will deploy U.S. Food and Drug Administration-cleared radiology AI algorithms through Microsoft’s Precision Imaging Network. The platform analyzes X-ray and CT scan images to help clinicians identify lung disease and is already used by hospitals across the United States.

The companies said the AI tools could help doctors detect hard-to-spot lung nodules and identify patients at earlier stages of disease, when treatment options are more effective. A key objective of the collaboration is to expand access to early lung cancer detection in medically underserved areas, including rural hospitals and community clinics.

Alexandra Goncalves, vice president and head of digital health at Bristol Myers Squibb, said the partnership combines Microsoft’s scalable imaging technology with Bristol Myers’ oncology expertise to create an AI-enabled workflow that supports faster and more accurate diagnosis of non-small cell lung cancer and guides patients toward appropriate care pathways.

Pharmaceutical companies are increasingly adopting AI to improve efficiency across research, development, and clinical workflows. The collaboration reflects a broader industry push to apply AI not only to drug discovery but also to diagnostics and patient care, particularly in oncology.